Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient perspective remains poorly understood. Herein, we aimed to identify the burden of disease and HRQoL impairment among patients with NASH-related compensated cirrhosis. METHODS: This targeted literature review sought first to identify the humanistic burden of disease from the perspective of patients with diagnosed NASH-cirrhosis and, secondly, to identify generic or disease-specific patient-reported outcome measures (PROMs) used to assess the impact of NASH-cirrhosis. Searches were conducted in bibliographical databases, grey or unpublished literature, liver disease websites, support group websites and online blogs. A quality assessment of specific PROMs was conducted. RESULTS: Patients with NASH-cirrhosis are reported to suffer from lower HRQoL than patients with non-cirrhotic NASH and the general population with respect to physical health/functioning, emotional health and worry, and mental health. Thirteen PROMs were identified, of which 4 were liver-disease specific: CLDQ, CLDQ-NAFLD, LDQoL and LDSI. The most commonly used measures do not comply with current industry or regulatory standards for PROMs and/or are not validated for use in a cirrhotic NASH population. CONCLUSIONS: Patients with NASH-cirrhosis have lower HRQoL and poorer physical health than patients with non-cirrhotic NASH. However, the literature lacked detail of the everyday impact on patients' lives. Currently, a number of PROMs are available to measure the impact of the disease in patients with chronic liver conditions. The lack of studies that include qualitative insights in this population mandates further exploration and research. LAY SUMMARY: It is not well understood how having non-alcoholic fatty liver disease (NAFLD)-related cirrhosis affects a person's everyday wellbeing and quality of life. Some research has been done with patients who have early stages of liver disease but not people with cirrhosis. We found that patients with NAFLD-related cirrhosis tended to have poorer health than patients without cirrhosis. But there was not very much information from patients themselves and there were no tools or questionnaires just for this group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 2×
“Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition worldwide, affecting approximately a quarter of the adult population.(1) NAFLD represents a spectrum of liver disease, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to the inflammatory form, non-alcoholic steato…”
BackgroundSelf-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Popay, J., Roberts, H., Sowden, A., Petticrew, M., Arai, L., Rodgers, M., Britten, N., Roen, K., & Duffy, S. (2006) · Lancaster University · doi:10.13140/2.1.1018.4643 · Cited by 2,070
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science
McKenna, S. P. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-86 · Cited by 319 · cited 1×
“In addition, regulatory bodies such as the United States 136 Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have an 137 expectation that regulatory submissions for new medicines will include information on the 138 impact of interventions from the patient perspective (17).”
BackgroundKennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0052-7 · Cited by 61 · cited 1×
“liver disease and diabetes could be problematic (73); cirrhotic 440 patients were reported as having worse physical health/functioning (27), emotional health, 441 mental health (50), and were reported to experience more pain than non-cirrhotic NAFLD 442 patients (39).”
Background
Cited by
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757
Self-citationLazarus, J. V., Mark, H. E., Villota-Rivas, M., Palayew, A., Carrieri, P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.025 · Cited by 267
Self-citationThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Metadata
- Authors
- McSweeney, L., Breckons, M., Fattakhova, G., Oluboyede, Y., Vale, L., Ternent, L., Balp, M.-M., Doward, L., Brass, C. A., Beyer, F., Sanyal, A., & Anstee, Q. M.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 2
- Issue
- 3
- Pages
- 100099
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W3009253119
- Cited by
- 54
- References
- 7
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhepr.2020.100099
- The paper
- McSweeney, L., Breckons, M., Fattakhova, G., Oluboyede, Y., Vale, L., Ternent, L., Balp, M.-M., Doward, L., Brass, C. A., Beyer, F., Sanyal, A., & Anstee, Q. M. (2020). Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Reports. https://doi.org/10.1016/j.jhepr.2020.100099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.